阜阳治刺瘊的价格(阜阳哪个医院青春痘治的比较有名) (今日更新中)

SAN FRANCISCO, April 25 (Xinhua) -- Oracle Corp. on Monday announced that its co-president Safra Catz is taking the additional position as the software giant's chief financial officer (CFO), following the resignation of its current CFO Jeff Epstein.Epstein was named Oracle's CFO in September 2008, and had reported directly to Catz. Oracle didn't give details about Epstein's departure.Catz joined Oracle in April 1999 and has been its president since January 2004. She previously served as the company's CFO from November 2005 to September 2008."Safra already has the long-standing confidence of our employees, our Board and our shareholders," Oracle's chief executive officer Larry Ellison said in a statement, adding that " there is no more logical choice for CFO.""The CFO function has reported to Safra for a number of years and she's acted as Oracle's CFO in the past. She has the full support of the Board," noted Jeff Henley, chairman of Oracle's board of directors.

BEIJING, April 12 (Xinhuanet) -- The elderly have a difficult time with multi-tasking as a study suggests that older brains behave differently when it comes to switching between two tasks, according to media reports on Tuesday.Researchers used functional magnetic resonance imaging (FMRI) to analyze brain activity in 20 people over age 60 by asking them to contemplate outdoor photos shown briefly. Then the elderly were presented with the picture of a face and asked to determine its gender and age, before being asked to recall details from the original scene they viewed.Researchers then compared their results to a similar experiment with 20 younger adults and found the brains of older subjects were less capable of disengaging from the interruption and reestablishing the neural connections necessary to switch back to focusing on the original memory."Unlike younger individuals, older adults failed to both disengage from the interruption and re-establish functional connections associated with the disrupted memory network," write Wesley C. Clapp of the University of California, San Francisco, and colleagues in the Proceedings of the National Academy of Sciences.The study, published in the online edition of the journal Proceedings of the National Academy of Sciences, sheds new lights into a growing body of studies showing that one's ability to move from one task to another in quick succession becomes more difficult with age.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

ABU DHABI, Feb. 10 (Xinhua) -- China is willing to deepen friendship, broaden cooperation, and enhance coordination with the United Arab Emirates (UAE) in international and regional affairs, visiting Chinese Foreign Minister Yang Jiechi said Thursday.During a meeting with Abu Dhabi Crown Prince Sheikh Mohammed bin Zayed Al Nahyan, Yang said China and the UAE have witnessed in recent years rapid development in their bilateral ties, with closer high-level contacts, increasingly strengthened mutual political trust, fruitful cooperation in such areas as trade and economy, and broadened cultural exchanges.China has praised the UAE's support in Xinjiang-related and human rights issues, he added.For his part, Sheikh Mohammed said the UAE-China relations are currently at an important period of in-depth development and faced with good opportunities.The UAE attaches great importance to its relations with China and hopes to cement the traditional friendship between the two countries and develop pragmatic cooperation in various fields, he added.Sheikh Mohammed said the UAE expects that China will continue to play a positive role in international and regional affairs.Earlier in the day, Yang also met with his UAE counterpart Sheikh Abdullah bin Zayed Al Nahyan. Both sides reached broad consensus after exchanging views on bilateral ties and regional issues of common concern.The Chinese foreign minister arrived in the UAE capital of Abu Dhabi late Wednesday for an official visit to the Gulf nation.

BEIJING, March 24 (Xinhuanet) -- Mozilla's newly launched Firefox 4 Web browser was downloaded nearly 7 million times worldwide in the first 24 hours, according to media reports.The number was almost triple the 2.4 million downloads that Microsoft reported in the first 24 hours after the Internet Explorer 9 (IE9) was released.Nevertheless, the number lagged behind the record-breaking performance of Firefox 3, which was downloaded more than 8 million times in the first day after launch in mid-2008.Statistics show that Firefox 4 has attracted interest from around the world, with 44 percent downloads in Europe, 26 percent in North America. and 20 percent in Asia.Mozilla launched Firefox 4 on Tuesday at around 10:00 a.m. EDT to compete with Microsoft's IE9 and Google Chrome.The new Web browser was originally scheduled to ship last November, but bugs delayed the release into early this year.Firefox trumped IE9 in the first day download contest because it runs on Windows XP, the 10-year-old operating system that IE9 doesn't support.

来源：资阳报